Vanwege de belangrijke rol die glucosamine heeft als bouwsteen van het kraakbeen, wordt het al tientallen jaren toegepast ter voorkoming en bestrijding van artrose en is het in meer dan 60 landen als geneesmiddel geregistreerd. De laatste jaren is glucosamine echter in diskrediet gebracht, door diverse onderzoeken en (meta)analyses waarin twijfel werd uitgesproken over het nut van glucosamine bij gewrichtsproblemen.
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Trefwoorden:
Figuren
Verschenen in
Referenties
1. Aghazadeh-Habashi A, Fakhreddin Jamali. The Glucosamine
Controversy: A Pharmacokinetic Issue. J Pharm
Pharmaceut Sci 2011; 14(2): 264 – 273.
2. Jordan KM et al. EULAR Recommendations 2003: An
evidence based approach to the management of knee osteoarthritis:
Report of a Task Force of the Standing Committee
for International Clinical Studies including Therapeutic
Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-1155.
3. Daniel O Clegg, Domenic J Reda et al. Glucosamine,
Chondroitin Sulfate, and the Two in Combination for Painful
Knee Osteoarthritis. The New England Journal of Medicine
2006 354(8): 795-808.
4. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL,
Singer NG, et al. Clinical efficacy and safety of glucosamine,
chondroitin sulphate, their combination, celecoxib or placebo
taken to treat osteoarthritis of the knee: 2-year results
from GAIT. Ann Rheum Dis 2010 Aug;69(8):1459-1464.
5. Arthritis Foundation Statement on the Glucosamine/
chondroitin Arthritis Intervention Trial. US Newswire
11/14/2005
6. Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton
NJ, et al. Effects of glucosamine, chondroitin, or placebo
in patients with osteoarthritis of hip or knee: network metaanalysis.
BMJ 2010 Sep 16;341:c4675.
7. Rovati LC, F Girolami et al. Crystalline glucosamine
sulfate in the management of knee osteoarthritis: efficacy,
safety and pharmacokinetic properties. Ther Adv Musculoskelet
Dis. 2012 June 4(3): 167-180.
8. Adebowale AO, Cox DS et al. Analysis of glucosamine
and chondroitin sulfate content in marketed products and
the Caco-2 permeability of chondroitin sulfate raw materials.
J Am Nutraceut Ass 2000 3(1), 37-45
9. Russel AS, Aghazadeh-Habashi A, Jamali F. Active
ingredient inconsistency of commercially available glucosamine
sulfate products. J. Rheumatol 2002 29(11): 2407-9.
10. ZiQi Zhou J, Waszkuc T, Mohammed F. Determination
of glucosamine in raw materials and dietary supplements
containing glucosamine sulphate and/or glucosamine hydrochloride
by high-performance liquid chromatography
with FMOC-Su derivatization: collaborative study. Journal
of APAC International 2005 88(4): 1048-1058.
11. Phitak T, Pothacharoen P, Kongtawelert P. Comparison
of glucose derivates on cartilage degradation. BMC Musculoskelatal
Disorders 2010 11: 162
12. Osaki T, Azuma K et al. Metabolomic analyses of blood
plasma after oral administration of D-glucosamine hydrochloride
to dogs. Mar Drugs 2012 10(8): 1873-1882.
13. Calamia V, Ruiz-Romero C et al. Pharmacoproteomic
study of the effects of chondroitin and glucosamine sulfate
on human articular chondrocytes. Arthritis Res Ther. 2010
12(4): R138
14. Lotz M, B Carames. Autophagy and cartilage homeostasis
mechanisms in joint health, aging and osteoarthritis.
Nat Rev Rheumatol 2011 7(10): 579-587
15. Beatriz Caramés, William Kiosses et al. Glucosamine
Regulates Autophagy In Vitro and In Vivo Department of
Molecular and Experimental Medicine, Core Microscopy
Facility, The Scripps Research Institute, La Jolla, CA, USA.
16. Glucosamine, A nutritional supplement that may counter
the effects of aging on joint health. Regenasure® White
Paper Cargill
17. Alyaa Ibrahim, Mohammed H et al. Absorption and
bioavailability of glucosamine in the rat. Journal of Pharmaceutical
Sciences 2012 101(7), 2574-2583
18. Jackson CG, Plaas AH et al. The human pharmacokinetics
of oral ingestion of glucosamine and chondroitin
sulfate taken separately or in combination. Osteoarthritis
Cartilage 2010 18(3): 297-302.
19. Hatchcock J and Shao A. Risk assessment for glucosamine
and chondroitin sulfate. Regulatory Toxicology and
Pharmacology 2007 (47): 78-83
20. Simon RR, Leeds AR et al. A comprehensive review of
oral glucosamine use and effects on glucose metabolism in
normal and diabetic individuals. Diabetes Metab Res Rev
2011 27(11): 14-27.
21. Persiani S, LC Rovati et al. Glucosamine oral bioavailability
and plasma pharmacokinetics after increasing doses
of crystalline glucosamine sulfate in man. Osteoarthritis
Cartilage 2005 13(12): 1041-9
22. Kulkani C, A Leena et al. A randomized comparatitive
study of safety and efficacy of immediate release glucosamine
HCl and glucosamine HCl sustained release formulation
in the treatment of knee osteoarthritis: A proof of concept
study. J Pharmacol Pharmacother 2012 3(1), 48-54
